Global vaccination policy this week feels less like harmonized orchestration and more like controlled fragmentation—with a purpose. European and Western Pacific advisory groups are quietly locking in 2026–2027 respiratory strategies that double down on older adults and high‑risk groups, implicitly signaling that broad, population‑wide boosting is yesterday’s paradigm. In the United States, the widening gap between the CDC’s slimmed‑down 2026 childhood schedule and the AAP’s more comprehensive stance is now a live stress‑test of how far “risk‑based” frameworks can stretch before they start to look like under‑vaccination by design. Globally, aligned WHO/EMA influenza strain calls give manufacturers a clear technical target, but GNN, Gavi, and CEPI are steadily raising the bar: functioning NITAGs, regional manufacturing, and credible end‑to‑end access plans are becoming prerequisites, not “nice to have” accessories. In that environment, being first to market matters less than fitting cleanly into these increasingly sharp policy and equity frameworks. Asia and Western Pacific Australia...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!
